MSI-1436 lactate is primarily investigated for its potential therapeutic applications, particularly in the treatment of obesity and type 2 diabetes. It functions as an inhibitor of protein tyrosine phosphatase 1B (PTP1B), an enzyme involved in the regulation of insulin and leptin signaling pathways. By inhibiting PTP1B, MSI-1436 lactate enhances insulin sensitivity and leptin activity, which can lead to improved glucose metabolism and reduced body weight. This makes it a promising candidate for managing metabolic disorders. Additionally, research has explored its potential in treating certain cancers, as PTP1B inhibition may also disrupt pathways involved in tumor growth and survival. Its application in neurodegenerative diseases is also under investigation, given its potential to modulate cellular signaling pathways that affect neuronal health. Overall, MSI-1436 lactate represents a versatile compound with significant potential in addressing a range of complex health conditions.